Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 121 Neoplasm Metastasis 12 Prostate Cancer Metastatic 4 Oligometastatic Prostate Cancer 3 Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 3 Metastatic Hormone-sensitive Prostate Cancer 3 Adenocarcinoma 3 Radiation Injuries 2 Prostatic Diseases 2 Prostate CA 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Neoplasms 2 Metastatic Castration-resistant Prostate Cancer 2 Urologic Diseases 1 Urogenital Neoplasms 1 Triple Negative Breast Neoplasms 1 Stage IV Prostate Adenocarcinoma AJCC v7 1 Stage I Prostate Adenocarcinoma 1 Salivary Gland Neoplasms 1 Recurrence 1 Prostatic Neoplasms, Castration-Resistant 1 Prostate Adenocarcinoma 1 PSA Level Greater Than 0.03 1 Oligorecurrent and Oligoprogressive Prostate Cancer Patients 1 Non-metastatic, Hormone naïve Prostate Cancer 1 Neoplasm Recurrence, Local 1 Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1 Metastatic Hormone-Sensitive Prostate Cance 1 Metastatic Hormone Sensitive Prostate Cancer 1 Metastatic Castration-sensitive Prostate Cancer 1

Interventions

Prednisolone 1 BID protein, human 1 Androgen Antagonists 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Abiraterone Acetate × Androgen Antagonists × Clear all

NCT06768255 2025-01-10

mCRPC

Fudan University

Phase 3 Not yet recruiting

Abiraterone Acetate

Data powered by HemOnc (CC BY 4.0) Colophon ⚡